HRP20110595T1 - Deglikozilirani i desijalidirani dugi pentraksin ptx3 - Google Patents
Deglikozilirani i desijalidirani dugi pentraksin ptx3 Download PDFInfo
- Publication number
- HRP20110595T1 HRP20110595T1 HR20110595T HRP20110595T HRP20110595T1 HR P20110595 T1 HRP20110595 T1 HR P20110595T1 HR 20110595 T HR20110595 T HR 20110595T HR P20110595 T HRP20110595 T HR P20110595T HR P20110595 T1 HRP20110595 T1 HR P20110595T1
- Authority
- HR
- Croatia
- Prior art keywords
- long pentraxin
- pentraxin ptx3
- deglycosylated
- ptx3
- desialylated
- Prior art date
Links
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims abstract 25
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 claims abstract 25
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims abstract 25
- 238000000034 method Methods 0.000 claims 10
- 241000233866 Fungi Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 241001225321 Aspergillus fumigatus Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical class O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229940091771 aspergillus fumigatus Drugs 0.000 claims 3
- 230000022811 deglycosylation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 241000228212 Aspergillus Species 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001857 anti-mycotic effect Effects 0.000 claims 2
- 239000002543 antimycotic Substances 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229930183010 Amphotericin Natural products 0.000 claims 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 101710165315 Sialidase A Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940009444 amphotericin Drugs 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000015100 cartilage disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000001641 gel filtration chromatography Methods 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 claims 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000489A ITRM20040489A1 (it) | 2004-10-08 | 2004-10-08 | Pentraxina lunga ptx3 deglicosilata o desialidata. |
| PCT/EP2005/054860 WO2006037744A1 (en) | 2004-10-08 | 2005-09-28 | Deglycosylated and desialidated long pentraxin ptx3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110595T1 true HRP20110595T1 (hr) | 2011-09-30 |
Family
ID=35708940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110595T HRP20110595T1 (hr) | 2004-10-08 | 2011-08-11 | Deglikozilirani i desijalidirani dugi pentraksin ptx3 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7683032B2 (da) |
| EP (1) | EP1797120B1 (da) |
| JP (1) | JP5014999B2 (da) |
| KR (1) | KR101426783B1 (da) |
| CN (1) | CN101035805B (da) |
| AR (1) | AR051053A1 (da) |
| AT (1) | ATE509950T1 (da) |
| AU (1) | AU2005291280B2 (da) |
| BR (1) | BRPI0516554A (da) |
| CA (1) | CA2580426C (da) |
| CY (1) | CY1112440T1 (da) |
| DK (1) | DK1797120T3 (da) |
| ES (1) | ES2366370T3 (da) |
| HK (1) | HK1110870A1 (da) |
| HR (1) | HRP20110595T1 (da) |
| IT (1) | ITRM20040489A1 (da) |
| ME (1) | ME01947B (da) |
| MX (1) | MX2007003904A (da) |
| PL (1) | PL1797120T3 (da) |
| PT (1) | PT1797120E (da) |
| RS (1) | RS51900B (da) |
| SI (1) | SI1797120T1 (da) |
| TW (1) | TWI380995B (da) |
| WO (1) | WO2006037744A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| WO2009095403A1 (en) * | 2008-01-29 | 2009-08-06 | Tecnogen S.P.A. | Expression system and uses thereof for the production of human long pentraxin 3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| WO2003011902A1 (en) | 2001-07-27 | 2003-02-13 | Kenton S.R.L. | Identification of specific tumour antigens by selection of cdna libraries with sera |
| CN1231257C (zh) * | 2001-08-03 | 2005-12-14 | 希格马托制药工业公司 | 长pentraxin ptx3用于制备增加雌性动物生殖能力的药物中的用途 |
| ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
| ITRM20020191A1 (it) | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
| ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
-
2004
- 2004-10-08 IT IT000489A patent/ITRM20040489A1/it unknown
-
2005
- 2005-09-26 TW TW094133381A patent/TWI380995B/zh not_active IP Right Cessation
- 2005-09-28 MX MX2007003904A patent/MX2007003904A/es active IP Right Grant
- 2005-09-28 AT AT05789623T patent/ATE509950T1/de active
- 2005-09-28 CN CN2005800342474A patent/CN101035805B/zh not_active Expired - Fee Related
- 2005-09-28 KR KR1020077009215A patent/KR101426783B1/ko not_active IP Right Cessation
- 2005-09-28 ES ES05789623T patent/ES2366370T3/es active Active
- 2005-09-28 WO PCT/EP2005/054860 patent/WO2006037744A1/en active Application Filing
- 2005-09-28 PT PT05789623T patent/PT1797120E/pt unknown
- 2005-09-28 ME MEP-2011-356A patent/ME01947B/me unknown
- 2005-09-28 RS RS20110356A patent/RS51900B/en unknown
- 2005-09-28 US US11/575,346 patent/US7683032B2/en not_active Expired - Fee Related
- 2005-09-28 EP EP05789623A patent/EP1797120B1/en active Active
- 2005-09-28 SI SI200531343T patent/SI1797120T1/sl unknown
- 2005-09-28 JP JP2007535139A patent/JP5014999B2/ja not_active Expired - Fee Related
- 2005-09-28 PL PL05789623T patent/PL1797120T3/pl unknown
- 2005-09-28 DK DK05789623.5T patent/DK1797120T3/da active
- 2005-09-28 BR BRPI0516554-7A patent/BRPI0516554A/pt not_active IP Right Cessation
- 2005-09-28 CA CA2580426A patent/CA2580426C/en not_active Expired - Fee Related
- 2005-09-28 AU AU2005291280A patent/AU2005291280B2/en not_active Ceased
- 2005-10-05 AR ARP050104203A patent/AR051053A1/es not_active Application Discontinuation
-
2008
- 2008-02-06 HK HK08101469.2A patent/HK1110870A1/xx not_active IP Right Cessation
-
2010
- 2010-02-23 US US12/710,559 patent/US7833981B2/en not_active Expired - Fee Related
-
2011
- 2011-08-11 HR HR20110595T patent/HRP20110595T1/hr unknown
- 2011-08-17 CY CY20111100788T patent/CY1112440T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR051053A1 (es) | 2006-12-13 |
| BRPI0516554A (pt) | 2008-09-09 |
| US20070249021A1 (en) | 2007-10-25 |
| EP1797120A1 (en) | 2007-06-20 |
| CA2580426C (en) | 2015-01-13 |
| CA2580426A1 (en) | 2006-04-13 |
| DK1797120T3 (da) | 2011-09-05 |
| JP2008515846A (ja) | 2008-05-15 |
| PT1797120E (pt) | 2011-08-23 |
| CY1112440T1 (el) | 2015-12-09 |
| ATE509950T1 (de) | 2011-06-15 |
| HK1110870A1 (en) | 2008-07-25 |
| US20100209442A1 (en) | 2010-08-19 |
| US7833981B2 (en) | 2010-11-16 |
| CN101035805B (zh) | 2011-04-06 |
| EP1797120B1 (en) | 2011-05-18 |
| PL1797120T3 (pl) | 2011-12-30 |
| RS51900B (en) | 2012-02-29 |
| US7683032B2 (en) | 2010-03-23 |
| JP5014999B2 (ja) | 2012-08-29 |
| ES2366370T3 (es) | 2011-10-19 |
| ME01947B (me) | 2012-02-29 |
| AU2005291280B2 (en) | 2011-10-20 |
| KR101426783B1 (ko) | 2014-08-05 |
| KR20070083769A (ko) | 2007-08-24 |
| AU2005291280A1 (en) | 2006-04-13 |
| MX2007003904A (es) | 2007-06-07 |
| TW200628488A (en) | 2006-08-16 |
| ITRM20040489A1 (it) | 2005-01-08 |
| CN101035805A (zh) | 2007-09-12 |
| TWI380995B (zh) | 2013-01-01 |
| SI1797120T1 (sl) | 2011-12-30 |
| WO2006037744A1 (en) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118059T1 (el) | Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων | |
| HRP20110595T1 (hr) | Deglikozilirani i desijalidirani dugi pentraksin ptx3 | |
| HUP0300027A2 (en) | Nucleoside analogs with carboxamidine modified monocyclic base and process for their use | |
| BR0113822A (pt) | Vacina | |
| NZ597082A (en) | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases | |
| JO2403B1 (en) | Nickeloside derivatives antiviral | |
| MA33449B1 (fr) | Antigènes recombinants du vrs | |
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| MX2022011111A (es) | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. | |
| EA200601575A1 (ru) | Казеиновые пептиды и их терапевтическое применение | |
| AP1771A (en) | 3'-Prodrugs of 2'-deoxy-?-L-nucleosides. | |
| TW200616968A (en) | Compound having basic substituent and application thereof | |
| JPH0687740A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）の複製を抑制する薬学的製剤 | |
| NO20063047L (no) | Vandige ciclesonidsuspensjoner for forstoving | |
| UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
| LV12766A (lv) | Composition of l-dopa esters | |
| EP0315591A3 (en) | Physiologically active substances, a process for the preparation thereof and pharmaceutical compositions containing them | |
| NZ510811A (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| DE602004014728D1 (de) | Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril | |
| JP2008515846A5 (da) | ||
| WO2003059246A3 (en) | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections | |
| DE60030732D1 (de) | Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis | |
| WO2007140011A3 (en) | Erythroid progenitor cells and methods for producing parvovirus b19 therein | |
| Paveglio et al. | The tick salivary protein, Salp15, inhibits the development of experimental asthma | |
| BRPI0409380A (pt) | composições farmacêuticas |